The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of response rate (RR), liver resection (LR), and toxicity (T) in 129 advanced colorectal cancer (CRC) patients (pts) treated with chronomodulated infusion of ironotecan (I), 5-fluorouracil/leucovorin (F/L), and oxaliplatin (O) (CHRONO-IFLO) with or without cetuximab (Cmab).
C. Garufi
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
A. Torsello
No relevant relationships to disclose
I. Sperduti
No relevant relationships to disclose
V. Ferraresi
No relevant relationships to disclose
M. Zeuli
No relevant relationships to disclose
A. Gelibter
No relevant relationships to disclose
C. Campanella
No relevant relationships to disclose
M. S. Pino
No relevant relationships to disclose
C. Nuzzo
No relevant relationships to disclose
S. Tumolo
No relevant relationships to disclose
F. Cognetti
No relevant relationships to disclose